News and Announcements
Blue Sky Biologicals Announces High Volume Manufacturing Agreement
- Published November 10, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Blue Sky Biologicals will produce a CBD based pain relief product for Soverign Funds Pty Ltd for the Australian Pharmaceutical marketplace.
- Marks one of the largest CBD production agreements in Australia
- Sovereign to market the Blue Sky manufactured product globally.
Vancouver, BC, November 8, 2017 – Blue Sky Biologicals Inc. (“BlueSky”) is pleased to announce that it has signed a Heads of Agreement (“HOA”) with Sovereign Funds Pty. Ltd. (“Sovereign”) of New South Wales, Australia for the production of Sovereign’s proprietary pain relief formulation.
With its GMP standard processing facility and the largest cannabidiol (CBD) and cannabinoid production capacity in the world, BlueSky will meet the rigorous specifications set by Sovereign while also fulfilling the volumes required.
“We are very pleased to be able to work with Sovereign to produce and supply their groundbreaking, CBD-based pain relief formula, CannadeineTM. Blue Sky Biologicals will continue to provide a completely organic and sustainable supply of industrial hemp-based CBD formulations to Sovereign to match their market growth” said Wade Hobson, Executive Vice President of BlueSky, managing the Asia Pacific region.
“Sovereign will now have the ability to distribute large volumes of their innovative pain relief products through a regulated pharmacy program, marking a milestone in the Australian medicinal marketplace, in compliance with the stringent Australian regulatory regime now in place for import and production” said Hobson.
About BlueSky
BlueSky is a vertically integrated global leader in CBD’s produced from its organic, hand harvested industrial hemp fields. BlueSky manufactures its CBD’s without the use of hexane or propylene glycol, maintaining high levels of purity through the entire product portfolio. BlueSky provides a full range of products within the four categories of Dietary Supplements, Personal Care, Functional Foods/Beverages and an exclusive Pet Care line.
About Sovereign
Sovereign is a producer of CBD and cannabinoid medicines. Sovereign is the proprietor of CannadolTM and CannadeineTM, which are the worldwide trademarks of their CBD medicine that derives from a stable breed and has a unique combination of cannabinoids for pain relief as well as prompt beneficial relief of many conditions and serious ailments.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
